Bradykinin restores left ventricular function, sarcomeric protein phosphorylation, and e/nNOS levels in dogs with Duchenne muscular dystrophy cardiomyopathy

Jin Bo Su, Olivier Cazorla, Stéphane Blot, Nicolas Blanchard-Gutton, Younss Ait Mou, Inès Barthélémy, Lucien Sambin, Carolina Carlos Sampedrano, Vassiliki Gouni, Yves Unterfinger, Pablo Aguilar, Jean Laurent Thibaud, Alain Bizé, Jean Louis Pouchelon, Hubert Dabiré, Bijan Ghaleh, Alain Berdeaux, Valérie Chetboul, Alain Lacampagne, Luc Hittinger

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Aims Cardiomyopathy is a lethal result of Duchenne muscular dystrophy (DMD), but its characteristics remain elusive. The golden retriever muscular dystrophy (GRMD) dogs produce DMD pathology and mirror DMD patients symptoms, including cardiomyopathy. We previously showed that bradykinin slows the development of pacing-induced heart failure. Therefore, the goals of this research were to characterize dystrophin-deficiency cardiomyopathy and to examine cardiac effects of bradykinin in GRMD dogs. Methods and results At baseline, adult GRMD dogs had reduced fractional shortening (28 ± 2 vs. 38 ± 2 in control dogs, P < 0.001) and left ventricular (LV) subendocardial dysfunction leading to impaired endo-epicardial gradient of radial systolic velocity (1.3 ± 0.1 vs. 3.8 ± 0.2 cm/s in control dogs, P < 0.001) measured by echocardiography. These changes were normalized by bradykinin infusion (1 g/min, 4 weeks). In isolated permeabilized LV subendocardial cells of GRMD dogs, tensioncalcium relationships were shifted downward and force-generating capacity and transmural gradient of myofilament length-dependent activation were impaired compared with control dogs. Concomitantly, phosphorylation of sarcomeric regulatory proteins and levels of endothelial and neuronal nitric oxide synthase (e/nNOS) in LV myocardium were significantly altered in GRMD dogs. All these abnormalities were normalized in bradykinin-treated GRMD dogs. Conclusion sCardiomyopathy in GRMD dogs is characterized by profound LV subendocardial dysfunction, abnormal sarcomeric protein phosphorylation, and impaired e/nNOS, which can be normalized by bradykinin treatment. These data provide new insights into the pathophysiological mechanisms accounting for DMD cardiomyopathy and open new therapeutic perspectives. Published on behalf of the European Society of Cardiology. All rights reserved.

Original languageEnglish
Pages (from-to)86-96
Number of pages11
JournalCardiovascular Research
Volume95
Issue number1
DOIs
Publication statusPublished - 1 Jul 2012
Externally publishedYes

Fingerprint

Nitric Oxide Synthase Type I
Duchenne Muscular Dystrophy
Nitric Oxide Synthase Type III
Bradykinin
Cardiomyopathies
Left Ventricular Function
Muscular Dystrophies
Phosphorylation
Dogs
Proteins
Left Ventricular Dysfunction
Dystrophin
Myofibrils
Echocardiography
Myocardium
Heart Failure
Pathology

Keywords

  • Bradykinin
  • Duchenne muscular dystrophy cardiomyopathy
  • Myofilament Ca sensitivity
  • Nitric oxide synthase
  • Protein phosphorylation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Physiology

Cite this

Bradykinin restores left ventricular function, sarcomeric protein phosphorylation, and e/nNOS levels in dogs with Duchenne muscular dystrophy cardiomyopathy. / Su, Jin Bo; Cazorla, Olivier; Blot, Stéphane; Blanchard-Gutton, Nicolas; Mou, Younss Ait; Barthélémy, Inès; Sambin, Lucien; Sampedrano, Carolina Carlos; Gouni, Vassiliki; Unterfinger, Yves; Aguilar, Pablo; Thibaud, Jean Laurent; Bizé, Alain; Pouchelon, Jean Louis; Dabiré, Hubert; Ghaleh, Bijan; Berdeaux, Alain; Chetboul, Valérie; Lacampagne, Alain; Hittinger, Luc.

In: Cardiovascular Research, Vol. 95, No. 1, 01.07.2012, p. 86-96.

Research output: Contribution to journalArticle

Su, JB, Cazorla, O, Blot, S, Blanchard-Gutton, N, Mou, YA, Barthélémy, I, Sambin, L, Sampedrano, CC, Gouni, V, Unterfinger, Y, Aguilar, P, Thibaud, JL, Bizé, A, Pouchelon, JL, Dabiré, H, Ghaleh, B, Berdeaux, A, Chetboul, V, Lacampagne, A & Hittinger, L 2012, 'Bradykinin restores left ventricular function, sarcomeric protein phosphorylation, and e/nNOS levels in dogs with Duchenne muscular dystrophy cardiomyopathy', Cardiovascular Research, vol. 95, no. 1, pp. 86-96. https://doi.org/10.1093/cvr/cvs161
Su, Jin Bo ; Cazorla, Olivier ; Blot, Stéphane ; Blanchard-Gutton, Nicolas ; Mou, Younss Ait ; Barthélémy, Inès ; Sambin, Lucien ; Sampedrano, Carolina Carlos ; Gouni, Vassiliki ; Unterfinger, Yves ; Aguilar, Pablo ; Thibaud, Jean Laurent ; Bizé, Alain ; Pouchelon, Jean Louis ; Dabiré, Hubert ; Ghaleh, Bijan ; Berdeaux, Alain ; Chetboul, Valérie ; Lacampagne, Alain ; Hittinger, Luc. / Bradykinin restores left ventricular function, sarcomeric protein phosphorylation, and e/nNOS levels in dogs with Duchenne muscular dystrophy cardiomyopathy. In: Cardiovascular Research. 2012 ; Vol. 95, No. 1. pp. 86-96.
@article{fe5497f99f6442a7954786de9c2ecf54,
title = "Bradykinin restores left ventricular function, sarcomeric protein phosphorylation, and e/nNOS levels in dogs with Duchenne muscular dystrophy cardiomyopathy",
abstract = "Aims Cardiomyopathy is a lethal result of Duchenne muscular dystrophy (DMD), but its characteristics remain elusive. The golden retriever muscular dystrophy (GRMD) dogs produce DMD pathology and mirror DMD patients symptoms, including cardiomyopathy. We previously showed that bradykinin slows the development of pacing-induced heart failure. Therefore, the goals of this research were to characterize dystrophin-deficiency cardiomyopathy and to examine cardiac effects of bradykinin in GRMD dogs. Methods and results At baseline, adult GRMD dogs had reduced fractional shortening (28 ± 2 vs. 38 ± 2 in control dogs, P < 0.001) and left ventricular (LV) subendocardial dysfunction leading to impaired endo-epicardial gradient of radial systolic velocity (1.3 ± 0.1 vs. 3.8 ± 0.2 cm/s in control dogs, P < 0.001) measured by echocardiography. These changes were normalized by bradykinin infusion (1 g/min, 4 weeks). In isolated permeabilized LV subendocardial cells of GRMD dogs, tensioncalcium relationships were shifted downward and force-generating capacity and transmural gradient of myofilament length-dependent activation were impaired compared with control dogs. Concomitantly, phosphorylation of sarcomeric regulatory proteins and levels of endothelial and neuronal nitric oxide synthase (e/nNOS) in LV myocardium were significantly altered in GRMD dogs. All these abnormalities were normalized in bradykinin-treated GRMD dogs. Conclusion sCardiomyopathy in GRMD dogs is characterized by profound LV subendocardial dysfunction, abnormal sarcomeric protein phosphorylation, and impaired e/nNOS, which can be normalized by bradykinin treatment. These data provide new insights into the pathophysiological mechanisms accounting for DMD cardiomyopathy and open new therapeutic perspectives. Published on behalf of the European Society of Cardiology. All rights reserved.",
keywords = "Bradykinin, Duchenne muscular dystrophy cardiomyopathy, Myofilament Ca sensitivity, Nitric oxide synthase, Protein phosphorylation",
author = "Su, {Jin Bo} and Olivier Cazorla and St{\'e}phane Blot and Nicolas Blanchard-Gutton and Mou, {Younss Ait} and In{\`e}s Barth{\'e}l{\'e}my and Lucien Sambin and Sampedrano, {Carolina Carlos} and Vassiliki Gouni and Yves Unterfinger and Pablo Aguilar and Thibaud, {Jean Laurent} and Alain Biz{\'e} and Pouchelon, {Jean Louis} and Hubert Dabir{\'e} and Bijan Ghaleh and Alain Berdeaux and Val{\'e}rie Chetboul and Alain Lacampagne and Luc Hittinger",
year = "2012",
month = "7",
day = "1",
doi = "10.1093/cvr/cvs161",
language = "English",
volume = "95",
pages = "86--96",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Bradykinin restores left ventricular function, sarcomeric protein phosphorylation, and e/nNOS levels in dogs with Duchenne muscular dystrophy cardiomyopathy

AU - Su, Jin Bo

AU - Cazorla, Olivier

AU - Blot, Stéphane

AU - Blanchard-Gutton, Nicolas

AU - Mou, Younss Ait

AU - Barthélémy, Inès

AU - Sambin, Lucien

AU - Sampedrano, Carolina Carlos

AU - Gouni, Vassiliki

AU - Unterfinger, Yves

AU - Aguilar, Pablo

AU - Thibaud, Jean Laurent

AU - Bizé, Alain

AU - Pouchelon, Jean Louis

AU - Dabiré, Hubert

AU - Ghaleh, Bijan

AU - Berdeaux, Alain

AU - Chetboul, Valérie

AU - Lacampagne, Alain

AU - Hittinger, Luc

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Aims Cardiomyopathy is a lethal result of Duchenne muscular dystrophy (DMD), but its characteristics remain elusive. The golden retriever muscular dystrophy (GRMD) dogs produce DMD pathology and mirror DMD patients symptoms, including cardiomyopathy. We previously showed that bradykinin slows the development of pacing-induced heart failure. Therefore, the goals of this research were to characterize dystrophin-deficiency cardiomyopathy and to examine cardiac effects of bradykinin in GRMD dogs. Methods and results At baseline, adult GRMD dogs had reduced fractional shortening (28 ± 2 vs. 38 ± 2 in control dogs, P < 0.001) and left ventricular (LV) subendocardial dysfunction leading to impaired endo-epicardial gradient of radial systolic velocity (1.3 ± 0.1 vs. 3.8 ± 0.2 cm/s in control dogs, P < 0.001) measured by echocardiography. These changes were normalized by bradykinin infusion (1 g/min, 4 weeks). In isolated permeabilized LV subendocardial cells of GRMD dogs, tensioncalcium relationships were shifted downward and force-generating capacity and transmural gradient of myofilament length-dependent activation were impaired compared with control dogs. Concomitantly, phosphorylation of sarcomeric regulatory proteins and levels of endothelial and neuronal nitric oxide synthase (e/nNOS) in LV myocardium were significantly altered in GRMD dogs. All these abnormalities were normalized in bradykinin-treated GRMD dogs. Conclusion sCardiomyopathy in GRMD dogs is characterized by profound LV subendocardial dysfunction, abnormal sarcomeric protein phosphorylation, and impaired e/nNOS, which can be normalized by bradykinin treatment. These data provide new insights into the pathophysiological mechanisms accounting for DMD cardiomyopathy and open new therapeutic perspectives. Published on behalf of the European Society of Cardiology. All rights reserved.

AB - Aims Cardiomyopathy is a lethal result of Duchenne muscular dystrophy (DMD), but its characteristics remain elusive. The golden retriever muscular dystrophy (GRMD) dogs produce DMD pathology and mirror DMD patients symptoms, including cardiomyopathy. We previously showed that bradykinin slows the development of pacing-induced heart failure. Therefore, the goals of this research were to characterize dystrophin-deficiency cardiomyopathy and to examine cardiac effects of bradykinin in GRMD dogs. Methods and results At baseline, adult GRMD dogs had reduced fractional shortening (28 ± 2 vs. 38 ± 2 in control dogs, P < 0.001) and left ventricular (LV) subendocardial dysfunction leading to impaired endo-epicardial gradient of radial systolic velocity (1.3 ± 0.1 vs. 3.8 ± 0.2 cm/s in control dogs, P < 0.001) measured by echocardiography. These changes were normalized by bradykinin infusion (1 g/min, 4 weeks). In isolated permeabilized LV subendocardial cells of GRMD dogs, tensioncalcium relationships were shifted downward and force-generating capacity and transmural gradient of myofilament length-dependent activation were impaired compared with control dogs. Concomitantly, phosphorylation of sarcomeric regulatory proteins and levels of endothelial and neuronal nitric oxide synthase (e/nNOS) in LV myocardium were significantly altered in GRMD dogs. All these abnormalities were normalized in bradykinin-treated GRMD dogs. Conclusion sCardiomyopathy in GRMD dogs is characterized by profound LV subendocardial dysfunction, abnormal sarcomeric protein phosphorylation, and impaired e/nNOS, which can be normalized by bradykinin treatment. These data provide new insights into the pathophysiological mechanisms accounting for DMD cardiomyopathy and open new therapeutic perspectives. Published on behalf of the European Society of Cardiology. All rights reserved.

KW - Bradykinin

KW - Duchenne muscular dystrophy cardiomyopathy

KW - Myofilament Ca sensitivity

KW - Nitric oxide synthase

KW - Protein phosphorylation

UR - http://www.scopus.com/inward/record.url?scp=84862836692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862836692&partnerID=8YFLogxK

U2 - 10.1093/cvr/cvs161

DO - 10.1093/cvr/cvs161

M3 - Article

VL - 95

SP - 86

EP - 96

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 1

ER -